By Ricardo Torres-Rivera, Xevalics Consulting, LLC
Learn what regulators are already asking about AI, what quality must mean in this new context, and how organizations can begin building the governance infrastructure.
Defining combination product CQAs across drug and device enables an end-to-end control strategy that improves product quality from the start of development.
